MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades
$MLTX $SLRN $ORKA
https://stocktwits.com/news/equity/markets/moon-lake-stock-climbs-after-hours-retail-traders-shrug-off-record-plunge-more-wall-street-downgrades/chDwriYR3JN
BTIG reiterated $VRDN Buy/$61.
$ARGX $IMVT $SLRN $AMGN
BTIG said:
Enrollment in the Phase 3 trials REVEAL-1/2 of VRDN-003 (SC autoinjector IGF-1R mAb) has completed, with 132 patients enrolled in REVEAL-1 and 204 patients enrolled in REVEAL-2 (initial target enrollment of 117 and 195, respectively). 67% of enrollment in REVEAL-1 (active TED) and 56% of that in REVEAL-2 (chronic TED) came from the US.
Topline data for these studies remain on track for 1H26 and we continue to view the readout as reasonably de-risked as VRDN-003 shares the same binding domains as veligrotug.
We also expect payors to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option.
BTIG went on to say:
$SLRN Acelyrin is surging after a game-changing merger and promising drug pipeline. See why analysts say this biotech could skyrocket in 2025. https://biotechhealthx.com/biotech-news/acelyrin-slrn-is-exploding-in-2025-is-slrn-the-hottest-biotech-play-right-now/
$ALMS So being new here, am I understanding correctly that ALMS took on $SLRN for Acelyrin's cash position and then SLRN dissolved their drug research? Or is there more to this?
Thanks!
M&A
Acelyric Inc $SLRN merger with and into Alumis $ALMS
- Shareholders of SLRN received 0.4814 shares of ALMS for every 1 share of SLRN owned
More Information :
https://www.sec.gov/ix?doc=/Archives/edgar/data/1962918/000119312525122468/d105874d8k.htm
$ALMS $4.88 bid. *DAC $3.80 (5.13.25). EXIT $15.00 (long term)
FACT:
Alumis has completed its merger with ACELYRIN, Inc. ($SLRN)
note: Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned. ACELYRIN common stock has ceased trading and will no longer be listed on the NASDAQ Global Select Market.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
$SLRN Equity Corporate Actions Alert #2025 - 254
Information Regarding the Merger of ACELYRIN, Inc. (SLRN)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-254
SLRN expected to halt at 7:50pm ET tonight. Merger closing May 21, SLRN suspended effective May 22.
"At a special meeting held on May 19, 2025, the shareholders of ACELYRIN, Inc. (SLRN) approved the proposed merger with and into Alumis Inc (ALMS). The merger is tentatively scheduled to close prior to the market open on May 21, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 20, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (May 21st) and will be suspended effective May 22, 2025."
$VXRT $SLRN With a combined cash position of approximately $737 million — including $289 million from Alumis and $448 million from Acelyrin — Acelyrin said the merger should provide enough runway through multiple planned key data readouts into 2027.
Post-merger, Alumis shareholders will own about 52% of the combined company, with Acelyrin shareholders holding the remaining 48%.
Current price for ALMS is $5.65, and accordingly, the price for SLRN should be $5.65x0.4814 = $2.72.
But it's $2.25... $0.50 free money for current buyers
$SLRN Under the amended agreement, Acelyrin shareholders will receive 0.4814 of an Alumis common share for each Acelyrin common share held, according to the statement. The companies said this represents a "meaningful increase" over the initial agreement.
ALMS currently at $5.40, and SLRN's current price should be $2.60, but you can buy it right now for $2.15
$ALMS $4.83 bid. *DAC (dollar average cost based on $SLRN merger) $3.80. EXIT $15.00.
note: Alumis stockholders approve merger with ACELYRIN (SLRN), expected to close in the second quarter of 2025.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
